Shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $9.43 and last traded at $9.14, with a volume of 493329 shares trading hands. The stock had previously closed at $9.09.
Wall Street Analyst Weigh In
Several brokerages have weighed in on APLT. Royal Bank of Canada reiterated an "outperform" rating and issued a $12.00 price objective on shares of Applied Therapeutics in a research report on Wednesday, July 17th. Citigroup boosted their price objective on Applied Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. William Blair upgraded Applied Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Leerink Partners boosted their price objective on Applied Therapeutics from $11.00 to $14.00 and gave the company an "outperform" rating in a research report on Thursday, September 19th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $12.50.
Check Out Our Latest Stock Analysis on APLT
Applied Therapeutics Price Performance
The stock has a market capitalization of $1.06 billion, a PE ratio of -5.92 and a beta of 2.01. The company has a 50 day moving average price of $7.49 and a 200-day moving average price of $5.83.
Applied Therapeutics (NASDAQ:APLT - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The firm had revenue of $0.14 million during the quarter, compared to analysts' expectations of $10.00 million. As a group, equities analysts anticipate that Applied Therapeutics, Inc. will post -0.48 earnings per share for the current year.
Insider Activity
In related news, CEO Shoshana Shendelman sold 300,000 shares of the company's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $5.98, for a total value of $1,794,000.00. Following the sale, the chief executive officer now directly owns 5,167,853 shares of the company's stock, valued at $30,903,760.94. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 8.60% of the company's stock.
Institutional Investors Weigh In On Applied Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of Applied Therapeutics by 198.6% in the first quarter. Janus Henderson Group PLC now owns 6,414,642 shares of the company's stock worth $43,555,000 after acquiring an additional 4,266,179 shares during the last quarter. StemPoint Capital LP grew its stake in shares of Applied Therapeutics by 122.3% in the first quarter. StemPoint Capital LP now owns 2,017,016 shares of the company's stock worth $13,716,000 after acquiring an additional 1,109,864 shares during the last quarter. Artal Group S.A. purchased a new stake in shares of Applied Therapeutics in the first quarter worth $6,865,000. Propel Bio Management LLC grew its stake in shares of Applied Therapeutics by 13.7% in the first quarter. Propel Bio Management LLC now owns 6,111,906 shares of the company's stock worth $41,561,000 after acquiring an additional 736,924 shares during the last quarter. Finally, Peregrine Capital Management LLC purchased a new stake in shares of Applied Therapeutics in the second quarter worth $3,414,000. 98.31% of the stock is owned by hedge funds and other institutional investors.
About Applied Therapeutics
(
Get Free Report)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Further Reading
Before you consider Applied Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Therapeutics wasn't on the list.
While Applied Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
